Adults

Dosage varies significantly based on indication and patient response. For Duchenne muscular dystrophy, 0.9 mg/kg/day, typically ranging from 6 mg to 36 mg daily. For other conditions, initial doses typically range from 6-18 mg/day, adjusted based on response.

Elderly

Use with caution; lower initial doses may be considered.

Renal_impairment

No specific dose adjustment generally required, but monitor patients closely.

Onset

Varies based on indication, generally within hours to days.

Excretion

Primarily via urine (about 70%) and feces (about 30%) as metabolites.

Half life

The active metabolite (21-desacetyl deflazacort) has a half-life of 1.1 to 1.9 hours.

Absorption

Well absorbed orally. Peak plasma concentrations are reached within 0.5 to 2 hours.

Metabolism

Rapidly converted to its active metabolite, 21-desacetyl deflazacort, primarily by esterases. Further metabolized in the liver.

Anticoagulants

May alter anticoagulant effects, requiring dose adjustment.

Diuretics (e.g., furosemide)

Increased risk of hypokalemia.

Non-steroidal anti-inflammatory drugs (NSAIDs)

Increased risk of gastrointestinal ulceration.

CYP3A4 inhibitors (e.g., ketoconazole, ritonavir)

May increase deflazacort levels.